Since 2007, with collagen-based scaffolds and more than thirty patents filed in ophthalmology, orthopedics, dentistry, reconstructive and general surgical applications, the BOBC research team has prided itself on being able to develop a broad range of solutions to unmet needs through its core technology. As the intent for this restructuring, BOBC is taking another step forward, looking ahead to pursue international recognition and visibility of its R&D and marketing ability accompanied by its clinical and academic accomplishments and entrepreneurship so as to further expand its own product portfolio in the global market. In this respect, BOBC has recreated itself from a unidimensional technology developer into a company focused on global marketing of branded biomedical devices, while continuing to advance its R&D program.
The organizational restructure has made BOBC’s planned IPO in 2012 / 2013 competitive and possible, as the cooperation between BOBC and its wholly-owned subsidiaries, including AAE and Aeon Astron USA, can solidify corporate resources, synchronize organizational goals and visions, enable BOBC to recruit international and top-class talent, and streamline operations by bridging the gap in the business value chain.
This organizational restructure is a substantial step forward along the path of becoming the world’s leading company in bioengineering devices that provide high end regenerative solutions through state-of-art technology, and to bridge the gap in the value chain from R&D, manufacturing, customer service, and global marketing so as to bring about a total solution entrepreneurship in regenerative medicine that is socially responsible and passionate for human welfare.
Currently, BOBC is working with key opinion leaders on the development of Biocornea and Biolens. The Biocornea, or corneal implant, can serve as a corneal replacement, dispensing with the need for donor substitutes, which may provide the ultimate solution to the global scourge of corneal blindness. As for the Biolens, it is a collagen-derived contact lens aimed at allergy sufferers or those with dry eye conditions, accounting for around 10% of global population. The launch of these two products is estimated for 2013 and 2014.
For information and inquiry, please contact
Web: www.aeonastron.com
Mr. Sean Liu
Email: sean.liu@aeonastron.net
The Netherlands:
Tel: +31 71 3322280
Fax: +31 71 3322281
Taiwan:
Tel: +886 2 27088558
Fax: +886 2 27081379
